Table 1 Clinicopathological characteristics of 345 surgically treated primary lung adenocarcinomas grouped by EGFR and KRAS mutational status
From: Clinicopathological predictors of EGFR/KRAS mutational status in primary lung adenocarcinomas
Clinicopathological characteristics | EGFR+ (n=37) | KRAS+ (n=103) | EGFR–/KRAS– (n=205) | P-value |
|---|---|---|---|---|
Gender (n, %) | ||||
Female | 30 (81%) | 52 (49) | 116 (57) | 0.0051 |
Male | 7 (19) | 51 (49) | 89 (43) | |
Tumor stage (n, %) | ||||
I | 21 (57) | 65 (68) | 115 (61) | 0.8891 |
II | 8 (22) | 9 (9) | 27 (14) | |
III | 8 (22) | 21 (22) | 47 (25) | |
Tumor grade (n, %) | ||||
G1 | 6 (16) | 18 (17) | 30 (15) | 0.0983 |
G2 | 30 (81) | 65 (65) | 130 (63) | |
G3 | 1 (3) | 20 (19) | 44 (22) | |
Scar (n, %) | ||||
No | 15 (41) | 51 (50) | 92 (45) | 0.5045 |
Yes | 22 (59) | 50 (50) | 113 (55) | |
AL invasion (n, %) | ||||
No | 18 (49) | 50 (49) | 88 (45) | 0.5856 |
Yes | 19 (51) | 53 (51) | 117 (57) | |
Pleural invasion (n, %) | ||||
No | 21 (57) | 65 (64) | 126 (62) | 0.7545 |
Yes | 16 (43) | 37 (36) | 79 (38) | |
Smoking history (n, %) | ||||
Never | 14 (39) | 5 (5) | 22 (11) | |
Former | 18 (50) | 52 (53) | 107 (53) | <0.0001 |
Current | 4 (11 | 42 (42 | 73 (36 | |
Tumor-infiltrating lymphocytes (n, %) | ||||
Low | 34 (92) | 74 (72) | 41 (69) | 0.0187 |
High | 3 (8) | 29 (28) | 62 (31) | |
